MONTREAL, May 23, 2006 (PRIMEZONE) -- Viropro Inc. ("Viropro" or "The Company") (OTCBB:VPRO), a company constantly solidifying its reputation as an international expert in the production and set-up of technology transfers of therapeutic proteins to pharmaceutical companies for the treatment of diseases such as cancer, diabetes, hepatitis and multiple sclerosis, is honoured to welcome Professor Claude Griscelli as a new member of its Board of Directors. Prof. Claude Griscelli brings Viropro a wealth of experience gained in medical and scientific research focused on paediatrics, immunology, genetic therapy as well as in research management
Prof. Claude Griscelli was Professor of paediatrics and medical genetics at CHU Necker in Paris, France until 1972. He then successively became Advisor to the Minister for Higher Education and Research in 1993-1994, then Advisor to the Minister of Health in 2004 and 2005. As General Manager of INSERM (France National Institute of Health and Medical Research) from 1996 to 2001, he led medical research in France and participated in the coordination of the European scientific program. He was member of the Scientific Board of the ANRS (French National AIDS Research Body), the Curie and Pasteur Institutes of France between 1996 and 2001. He is currently Vice President Scientific and Medical Affairs at Wyeth, France since 2002.
"I am thrilled Prof. Griscelli accepted to join our Board of Directors," said Dr. Jean-Marie Dupuy, CEO of Viropro. "His achievements speak volumes in the medical and scientific fields and will be of enormous benefit to Viropro as it implements its growth strategy on international markets."
"It gives me great pleasure to join the other Viropro Board members. I believe the technological transfer of therapeutic molecules to emerging markets is of a major importance by allowing countries with unmet medical needs to treat more patients at a lower cost," said Prof. Griscelli.
Prof. Griscelli has been member of numerous international scientific committees such as the European Group for Immunodeficiency, President of the International Childhood Center INSERM, member of the World Health Organization Committees on Pediatric HIV Infection and Inherited Immunodeficiencies. He has been the recipient of many awards and honours including the title of 'Commandeur de la Legion d'honneur' in 2004. He authored more than 400 medical and scientific publications.
About Viropro Inc.
Viropro Inc. operates mainly through its subsidiary Viropro International Inc. with its head office in Montreal, Canada. Viropro is a company specializing in marketing its know-how and expertise in technology transfer for industrial production of therapeutic proteins. Besides today's announcement, Viropro has concluded other strategic alliances with renowned scientific and business partners, both at the national and international levels. Viropro relies on a business model built to generate short- and medium-term recurrent revenues while increasing the value of stock for both the company and its shareholders.
For more information on Viropro Inc, please visit our website on www.viropro.com
Viropro Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.